Tanespimycin monotherapy in relapsed multiple myeloma: Results of a phase 1 dose-escalation study

Paul G. Richardson, Asher A. Chanan-Khan, Melissa Alsina, Maher Albitar, David Berman, Marianne Messina, Constantine S. Mitsiades, Kenneth C. Anderson

Research output: Contribution to journalArticle

60 Scopus citations

Abstract

Tanespimycin, a heat shock protein 90 (HSP90) inhibitor, induces apoptosis in drug-sensitive and -resistant MM cell lines and in tumour cells from patients with relapsed MM. In this phase 1 dose-escalation study, the safety, plasma pharmacokinetics, and biological/antitumour activity of tanespimycin were evaluated in heavily pretreated patients with relapsed/refractory MM. Tanespimycin (150-525 mg/m2) was given on days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles. Non-haematological AEs included diarrhoea (59%), back pain (35%), fatigue (38%), and nausea (35%); haematological AEs included anaemia (24%) and thrombocytopenia (21%). One patient (3%) achieved minimal response (MR), with a progression-free survival (PFS) of 3 months, a 41% decrease from baseline in urine M protein, and a 33% decrease from baseline in serum M protein. Fifteen patients (52%) achieved SD with a median PFS of 2·1 months; 5/15 had reductions in serum M protein ranging from 7% to 38% and in urine M protein ranging from 6% to 91%. Mean HSP70 levels increased from day 1 h 0 to day 1 h 4 with further increases on day 11 h 0 and day 11 h 4, consistent with a therapeutic treatment effect. Tanespimycin monotherapy was well tolerated and demonstrated activity across all doses tested.

Original languageEnglish (US)
Pages (from-to)438-445
Number of pages8
JournalBritish journal of haematology
Volume150
Issue number4
DOIs
StatePublished - Aug 2010

Keywords

  • 17-AAG
  • HSP70
  • HSP90
  • Multiple myeloma
  • tanespimycin

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Tanespimycin monotherapy in relapsed multiple myeloma: Results of a phase 1 dose-escalation study'. Together they form a unique fingerprint.

  • Cite this

    Richardson, P. G., Chanan-Khan, A. A., Alsina, M., Albitar, M., Berman, D., Messina, M., Mitsiades, C. S., & Anderson, K. C. (2010). Tanespimycin monotherapy in relapsed multiple myeloma: Results of a phase 1 dose-escalation study. British journal of haematology, 150(4), 438-445. https://doi.org/10.1111/j.1365-2141.2010.08265.x